|
|
|
|
| LEADER |
01364 am a22002413u 4500 |
| 001 |
65912 |
| 042 |
|
|
|a dc
|
| 100 |
1 |
0 |
|a Lou, Sha
|e author
|
| 100 |
1 |
0 |
|a Massachusetts Institute of Technology. Department of Chemistry
|e contributor
|
| 100 |
1 |
0 |
|a Fu, Gregory C.
|e contributor
|
| 100 |
1 |
0 |
|a Lou, Sha
|e contributor
|
| 100 |
1 |
0 |
|a Fu, Gregory C.
|e contributor
|
| 700 |
1 |
0 |
|a Fu, Gregory C.
|e author
|
| 245 |
0 |
0 |
|a Enantioselective Alkenylation via Nickel-Catalyzed Cross-Coupling with Organozirconium Reagents
|
| 260 |
|
|
|b American Chemical Society,
|c 2011-09-21T19:09:09Z.
|
| 856 |
|
|
|z Get fulltext
|u http://hdl.handle.net/1721.1/65912
|
| 520 |
|
|
|a A new family of organometallic compounds, organozirconium reagents, are shown to serve as suitable partners in cross-coupling reactions of (activated) secondary alkyl electrophiles. Thus, the first catalytic method for coupling secondary α-bromoketones with alkenylmetal reagents has been developed, specifically, a mild, versatile, and stereoconvergent carbon−carbon bond-forming process that generates potentially labile β,γ-unsaturated ketones with good enantioselectivity.
|
| 520 |
|
|
|a National Institute of General Medical Sciences (U.S.) (grant R01-GM62871)
|
| 520 |
|
|
|a Novartis (Firm)
|
| 520 |
|
|
|a Merck Research Laboratories
|
| 546 |
|
|
|a en_US
|
| 655 |
7 |
|
|a Article
|
| 773 |
|
|
|t Journal of the American Chemical Society
|
